Pharmacogenomics of cytarabine in childhood leukemia

Pharmacogenomics. 2011 Dec;12(12):1629-32. doi: 10.2217/pgs.11.148.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Apoptosis
  • Biomarkers, Pharmacological
  • Child
  • Child, Preschool
  • Cytarabine / pharmacokinetics*
  • Cytarabine / therapeutic use
  • Deoxycytidine Kinase / genetics
  • Drug Resistance, Neoplasm / genetics*
  • Equilibrative Nucleoside Transporter 1 / genetics*
  • Gene Expression Regulation, Leukemic
  • Genetic Variation
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Signal Transduction

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Pharmacological
  • Equilibrative Nucleoside Transporter 1
  • SLC29A1 protein, human
  • Cytarabine
  • Deoxycytidine Kinase